{
    "clinical_study": {
        "@rank": "90932", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if it is safe and effective to give thioctic acid and\n      deprenyl (selegiline hydrochloride), alone or in combination, to HIV-infected patients who\n      have mild to moderate dementia (a decline in their mental abilities)."
        }, 
        "brief_title": "A Study of Thioctic Acid and Deprenyl in HIV-Infected Patients With Dementia", 
        "condition": [
            "Cognitive Disorders", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Cognition Disorders", 
                "Dementia"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients are randomized to receive thioctic acid alone, deprenyl alone, thioctic\n      acid/deprenyl, or placebo alone for 10 weeks, after which all patients may receive active\n      drug on an open-label basis. Patients must have seven clinic visits."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Antiretrovirals provided dose has been stable for at least 6 weeks prior to study\n             entry.\n\n        Patients must have:\n\n          -  HIV seropositivity.\n\n          -  Mild to moderate cognitive impairment (problems with short term memory,\n             concentration, and feeling slowed down).\n\n          -  No active opportunistic CNS infection.\n\n          -  Ability to give informed consent.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Prior antiretrovirals provided dose has been stable for at least the past 6 weeks.\n\n          -  Prior thioctic acid or deprenyl.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Severe premorbid psychiatric illness including schizophrenia and major depression\n             that would interfere with study compliance.\n\n          -  CNS neoplasms.\n\n          -  Any other clinically significant condition or laboratory abnormality that would\n             preclude participation on study.\n\n          -  Current participation in other drug studies.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Chemotherapy for malignancy.\n\n        Patients with the following prior conditions are excluded:\n\n          -  History of chronic neurological disorders such as serious head injury, documented\n             stroke, multiple sclerosis, uncontrolled epilepsy, Tourette's syndrome, and other\n             neurodegenerative processes such as Huntington's disease.\n\n          -  Prior participation in this study.\n\n          -  History of adverse reaction/allergy to thioctic acid or deprenyl.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Other investigational drugs within 30 days prior to study entry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "32", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002154", 
            "org_study_id": "250A", 
            "secondary_id": "03-D95"
        }, 
        "intervention": [
            {
                "intervention_name": "Thioctic acid", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Selegiline hydrochloride", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Thioctic Acid", 
                "Selegiline"
            ]
        }, 
        "keyword": [
            "Drug Therapy, Combination", 
            "Cognition Disorders", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "Thioctic Acid", 
            "Selegiline"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "212876965"
                    }, 
                    "name": "Johns Hopkins Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Columbia Univ"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14642"
                    }, 
                    "name": "Univ of Rochester Med Ctr"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Parallel Group, Placebo-Controlled, Tolerability and Safety Study of Thioctic Acid and Deprenyl in HIV Dementia", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002154"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The Dana Foundation", 
                "agency_class": "Other"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 1996"
    }, 
    "geocoordinates": {
        "Columbia Univ": "40.714 -74.006", 
        "Johns Hopkins Hosp": "39.29 -76.612", 
        "Univ of Rochester Med Ctr": "43.161 -77.611"
    }
}